DBV Technologies S.A. (DBVT)
Largest Insider Buys in Sector
DBVT Stock Price History Chart
DBVT Stock Performance
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Insider Activity of DBV Technologies S.A.
Over the last 12 months, insiders at DBV Technologies S.A. have bought $15,812 and sold $4,946 worth of DBV Technologies S.A. stock.
On average, over the past 5 years, insiders at DBV Technologies S.A. have bought $29,176 and sold $5,225 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Tasse Daniel (CHIEF EXECUTIVE OFFICER) — $14,188. Ndu Adora (director) — $1,624.
The last purchase of 17,094 shares for transaction amount of $14,188 was made by Tasse Daniel (CHIEF EXECUTIVE OFFICER) on 2024‑03‑08.
List of Insider Buy and Sell Transactions, DBV Technologies S.A.
| 2024-11-25 | Sale | Chief Medical Officer | 565 0.0019% | $0.57 | $322 | +38.80% | ||
| 2024-11-22 | Sale | Chief Medical Officer | 342 0.0011% | $0.53 | $181 | +47.23% | ||
| 2024-11-21 | Sale | Chief Medical Officer | 2,350 0.0074% | $0.54 | $1,269 | +41.39% | ||
| 2024-07-29 | Sale | Chief Medical Officer | 1,785 0.0103% | $0.98 | $1,749 | -20.43% | ||
| 2024-05-24 | Sale | Chief Medical Officer | 660 0.0053% | $1.36 | $898 | -34.67% | ||
| 2024-05-22 | Sale | Chief Medical Officer | 382 0.0031% | $1.38 | $527 | -35.28% | ||
| 2024-03-08 | CHIEF EXECUTIVE OFFICER | 17,094 0.0833% | $0.83 | $14,188 | -47.73% | |||
| 2024-02-06 | director | 1,825 0.0095% | $0.89 | $1,624 | -48.21% | |||
| 2023-11-22 | Sale | Chief Medical Officer | 2,245 0.0229% | $1.74 | $3,906 | -27.94% | ||
| 2023-08-25 | director | 12,000 0.1071% | $1.52 | $18,240 | -46.31% | |||
| 2023-08-01 | director | 15,000 0.1426% | $1.62 | $24,300 | -47.89% | |||
| 2023-05-24 | Sale | Chief Medical Officer | 469 0.0097% | $3.54 | $1,660 | -51.19% | ||
| 2022-11-24 | Sale | Chief Medical Officer | 1,792 0.0303% | $2.88 | $5,161 | +11.76% |
Insider Historical Profitability
| Mohideen Pharis | Chief Medical Officer | 111110 0.5417% | $4.62 | 0 | 9 | |
| Tasse Daniel | CHIEF EXECUTIVE OFFICER | 17094 0.0833% | $4.62 | 1 | 0 | |
| Ndu Adora | director | 1825 0.0089% | $4.62 | 1 | 0 | |
| SOLAND DANIEL B | director | 20000 0.0975% | $4.62 | 1 | 0 | <0.0001% |
| MORRIS TIMOTHY E | director | 12000 0.0585% | $4.62 | 1 | 0 | <0.0001% |